Leerink Partnrs Brokers Lower Earnings Estimates for ELAN

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities researchers at Leerink Partnrs dropped their Q1 2025 EPS estimates for Elanco Animal Health in a note issued to investors on Tuesday, February 25th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings per share of $0.29 for the quarter, down from their previous estimate of $0.32. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.80 EPS, FY2027 earnings at $1.16 EPS and FY2028 earnings at $1.37 EPS.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the business earned $0.08 EPS. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year.

A number of other brokerages have also issued reports on ELAN. Stifel Nicolaus dropped their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Barclays dropped their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday. Leerink Partners assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price on the stock. UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Morgan Stanley dropped their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $15.57.

Elanco Animal Health Trading Up 4.2 %

NYSE:ELAN opened at $11.15 on Thursday. Elanco Animal Health has a 12 month low of $10.20 and a 12 month high of $18.80. The firm has a market cap of $5.51 billion, a price-to-earnings ratio of 27.88, a P/E/G ratio of 2.50 and a beta of 1.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The company’s 50 day moving average is $11.74 and its 200-day moving average is $13.06.

Institutional Investors Weigh In On Elanco Animal Health

Institutional investors have recently bought and sold shares of the business. AM Squared Ltd acquired a new stake in Elanco Animal Health during the third quarter worth $34,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $35,000. CoreCap Advisors LLC acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at $29,000. Farther Finance Advisors LLC boosted its stake in shares of Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after purchasing an additional 2,044 shares in the last quarter. Finally, Venturi Wealth Management LLC boosted its stake in shares of Elanco Animal Health by 89.9% in the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.